Hudson Bay Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Hudson Bay Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-80,000	Closed	-$1.19M	–	499
2019 Q2	$1.19M	Buy	80,000 +20,000	+33%	+$361K	0.03%	317
2019 Q1	$1.49M	Buy	60,000 +10,000	+20%	+$251K	0.02%	511
2018 Q4	$898K	Sell	50,000 -116,100	-70%	-$2.37M	0.01%	650
2018 Q3	$4.88M	Buy	166,100 +116,100	+232%	+$4.49M	0.06%	296
2018 Q2	$2.27M	Sell	50,000 -10,000	-17%	-$486K	0.03%	478
2018 Q1	$3.17M	Hold	60,000	–	–	0.07%	330
2017 Q4	$4.08M	Buy	60,000 +20,000	+50%	+$1.4M	0.09%	198
2017 Q3	$3.3M	Sell	40,000 -20,000	-33%	-$1.59M	0.08%	193
2017 Q2	$5.62M	Buy	60,000 +20,000	+50%	+$1.22M	0.11%	167
2017 Q1	$2.55M	Buy	+40,000	New	+$2.43M	0.03%	410
2016 Q4	–	Sell	-35,000	Closed	-$1.26M	–	727
2016 Q3	$1.26M	Buy	+35,000	New	+$751K	0.03%	283

Other funds holding CLVS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ECP

Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Hudson Bay Capital Management's CLVS Position: Q3 2019 in Review

Hudson Bay Capital Management sold out of Clovis Oncology, Inc. (CLVS) in Q3 2019, closing a stake of 80,000 shares — an estimated $1.19M sold.

Hudson Bay Capital Management first reported a position in CLVS in Q3 2016 and held it in 11 quarters. The position peaked at $5.62M in Q2 2017. 153 funds tracked by Wall St. Rank hold CLVS as of Q3 2019.

Hudson Bay Capital Management reported no remaining Clovis Oncology, Inc. position as of Q3 2019 after selling out during the quarter.
Hudson Bay Capital Management sold 80,000 Clovis Oncology, Inc. shares in Q3 2019, an estimated $1.19M.
Hudson Bay Capital Management first reported a position in Clovis Oncology, Inc. in Q3 2016 and held it in 11 quarters.
Hudson Bay Capital Management's Clovis Oncology, Inc. position peaked at $5.62M in Q2 2017.
153 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2019.

Based on Hudson Bay Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.